Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos

View ORCID ProfileOE Babalola, View ORCID ProfileCO Bode, View ORCID ProfileAA Ajayi, View ORCID ProfileFM Alakaloko, View ORCID ProfileIE Akase, View ORCID ProfileE Otrofanowei, View ORCID ProfileOB Salu, View ORCID ProfileWL Adeyemo, View ORCID ProfileAO Ademuyiwa, S Omilabu
doi: https://doi.org/10.1101/2021.01.05.21249131
OE Babalola
1Department of Ophthalmology, Bingham University, Karu/Jos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for OE Babalola
  • For correspondence: bablo57@gmail.com
CO Bode
2Department of Surgery, Faculty of Clinical Sciences, College of Medicine & Lagos University Teaching Hospital, Lagos, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for CO Bode
AA Ajayi
3Division of Hypertension and Clinical pharmacology, Keck Department of Medicine, Baylor College of Medicine Houston Texas, TX 77030 USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for AA Ajayi
FM Alakaloko
4Department of Surgery, Lagos University Teaching Hospital, Lagos, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for FM Alakaloko
IE Akase
5Department of Medicine, Lagos University Teaching Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for IE Akase
E Otrofanowei
6Department of Medicine, Faculty of Clinical Sciences, College of Medicine/Lagos University Teaching Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for E Otrofanowei
OB Salu
7Centre for Human and Zoonotic Virology, Central Research Laboratory/Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for OB Salu
WL Adeyemo
8Department of Oral and Maxillofacial Surgery, College of Medicine, University of Lagos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for WL Adeyemo
AO Ademuyiwa
2Department of Surgery, Faculty of Clinical Sciences, College of Medicine & Lagos University Teaching Hospital, Lagos, Nigeria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for AO Ademuyiwa
S Omilabu
7Centre for Human and Zoonotic Virology, Central Research Laboratory/Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction In vitro studies have shown the efficacy of Ivermectin (IV) to inhibit the SARS - CoV-2 viral replication, but questions remained as to In-vivo applications. We set out to explore the efficacy and safety of Ivermectin in persons infected with COVID19.

Methods We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in RT - PCR proven COVID 19 positive patients. 62 patients were randomized to 3 treatment groups. (A) IV 6mg regime, (B)IV 12 mg regime (given Q84hrs for 2weeks) (C, control) Lopinavir/Ritonavir. All groups plus standard of Care.

Results The Days to COVID negativity [DTN] was significantly and dose dependently reduced by IV (p = 0.0066). The DTN for Control were, = 9.1+/−5.2, for A 6.0 +/− 2.9, and for B 4.6 +/−3.2. 2 Way repeated measures ANOVA of ranked COVID 19 + / − scores at 0, 84, 168, 232 hours showed a significant IV treatment effect (p=0.035) and time effect (p <0.0001). IV also tended to increase SPO2 % compared to controls, p = 0.073, 95% CI - 0.39 to 2.59 and increased platelet count compared to C (p = 0.037) 95%CI 5.55 - 162.55 × 103/ml. The platelet count increase was inversely correlated to DTN (r = −0.52, p = 0.005). No SAE was reported.

Conclusions 12 mg IV regime may have superior efficacy. IV should be considered for use in clinical management of SARS-Cov-2, and may find applications in community prophylaxis in high-risk areas.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

ISRCTN40302986

Clinical Protocols

https://www.ivercovid.com

Funding Statement

Funding support provided by 1. Rachel Eye Center, Abuja 2. Crystal Optics (Nig) ltd.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

1. Human Research Ethical Committee Lagos University Teaching Hospital Lagos. 2. National Agency for Food and Drug Administration and Control. NAFDAC.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data referred to in the manuscript is available

https://www.ivercovid.com

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
OE Babalola, CO Bode, AA Ajayi, FM Alakaloko, IE Akase, E Otrofanowei, OB Salu, WL Adeyemo, AO Ademuyiwa, S Omilabu
medRxiv 2021.01.05.21249131; doi: https://doi.org/10.1101/2021.01.05.21249131
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose response study in Lagos
OE Babalola, CO Bode, AA Ajayi, FM Alakaloko, IE Akase, E Otrofanowei, OB Salu, WL Adeyemo, AO Ademuyiwa, S Omilabu
medRxiv 2021.01.05.21249131; doi: https://doi.org/10.1101/2021.01.05.21249131

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (528)
  • Epidemiology (9998)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2441)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1634)
  • Health Policy (750)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (530)
  • Infectious Diseases (except HIV/AIDS) (11854)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2271)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (728)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (281)
  • Psychiatry and Clinical Psychology (2279)
  • Public and Global Health (4822)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)